Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

AstraZeneca, Lund, May 7 2014


Published on

Published in: Career, Technology, Business
  • Be the first to comment

  • Be the first to like this

AstraZeneca, Lund, May 7 2014

  1. 1. Lund May 7, 2014 Shalini Andersson, CVMD Mikael Varga, RIA Per-Erik Strömstedt, Discovery Sciences Magnus Klarqvist, RIA AstraZeneca R&D Mölndal
  2. 2. Our commitment to making a meaningful difference in healthcare is founded on our innovative science. The pursuit of scientific excellence that addresses unmet patient need guides everything we do. Pascal Soriot CEO Mission: To push the boundaries of science to deliver life-changing medicines
  3. 3. Om AstraZeneca With three strategic priorities Achieve Scientific Leadership Be a great place to work Return to growth Our strategy is focused on innovation
  4. 4. Increase proximity to bioscience clusters and co-locate around three strategic sites 4 Proximity to NIH, Johns Hopkins New site in Cambridge with close proximity to University of Cambridge and world class UK bioscience community Connections to Karolinska Institute & Medicon Valley Gaithersburg MölndalCambridge Leverage historical strength Respiratory and CV/Met Co-locate around biologics/specialty care Co-locate R&D in world-class science cluster
  5. 5. Our research and development To deliver the next generation Biologics Small Molecules Immuno - therapies Protein engineering Neuroscience Infection & Vaccines CV- Metabolism Respiratory, Inflammation & Autoimmunity Oncology Core Therapy Areas Opportunity-focused
  6. 6. • Two iMeds - RIA and CVMD • Safety and Discovery Sciences • A large Development organisation • Several centers of excellence, eg inhalation technologies and transgenics • Proximity to academic centers and Europes largest hospital AstraZeneca R&D Mölndal
  7. 7. A strong heritage to build on 6
  8. 8. 2,300 dedicated colleagues in Mölndal... 901 in Research – 2 iMeds 1,004 in Development - GMD 60 % women 40 % men 1,570 have an academic degree 570 have a PhD >30 professorers >30 post-docs …including >250 scientists from 30 countries who bring new insights, expertise and energy!
  9. 9. Our current focus in RIA • Respiratory, Inflammation & Autoimmunity (RIA)  Asthma  COPD (Chronic obstructive pulmonary disease)  Idiopathic Pulmonary Fibrosis  Rheumatology  Autoimmune disorders
  10. 10. COPD 10 AZ has a strong and continuing presence in front line COPD care based on bronchodilator/anti-inflammatory therapy What’s next? Hallmarks of COPD COPD is mixed disease with both airway obstructions and loss of functional lung Breathlessness in COPD is more than airflow obstruction
  11. 11. Our current focus in CVMD • Cardiovascular and Metabolic diseases (CVMD)  Diabetic Nephropathy  Cardiac Regeneration  Islet Health and Metabolism
  12. 12. Cardiac Regeneration Diabetic Nephropathy Islet Cell Health (Diabetes)
  13. 13. Cardiac Regeneration Goal To identify and develop small or large molecules that enhance endogenous regenerative capacity of the heart for the treatment of post-MI cardiac dysfunction and heart failure. Vision To launch a new therapy which will offer an entirely new treatment paradigm for patients who are dying of heart failure today. Induction of proliferation of existing cardiomyocytes Direct reprogramming of cardiac fibroblasts into cardiomyocytes or cardiac progenitors Activation of resident cardiac progenitor cells in the heart: Epicardial progenitor cells (EPDC) or cardiac stem cells (CSC)
  14. 14. Discovery Sciences 14 Per-Erik Strömstedt | May 7, 2014 | Discovery Sciences • Compound management • Biobanks (clinical samples) • Hit generation • SAR screening • Ion channel centre of excellence • Crystallography; first structures, iterative structures • NMR and other biophysical techniques • Fragment Chemistry • Chemical Biology • Computational biology • Cheminformatics • Predictive Chemistry • Compound collection enhancement • Proteins • Cells • Transgenics • Antibodies DS • Project support • Statistical qualification Discovery Sciences (DS) provides centralised, state-of-the art support for hit finding, lead optimization and target validation for all therapeutic research areas with AZ. • Assay development • High content biology assays
  15. 15. Partnering, collaborations and open innovation remain key to pushing the boundaries of science
  16. 16. We are driving science through collaborations… …more than 90 partnerships in the last three years
  17. 17. To deliver the next generation of medicines we must continue to find ways to combine our science with the best science that’s happening elsewhere Challenging ourselves to find new ways to break through the barriers and work more openly with scientists in other organisations who share our passion for patients and who can bring different perspectives to innovative research
  18. 18. Accessible through an Open Innovation Website
  19. 19. • Summerworker • Master’s thesis • Graduate programme • Post-Doc programme
  20. 20. Opportunities at AZ Mölndal 21 Author | 00 Month Year Set area descriptor | Sub level 1 60 Summer workers 2013 22 Master’s thesis students 6 Graduate students 33 Post-Docs With the ambition to increase …
  21. 21. AstraZeneca Post-Doc Programme Investing in innovative science The next generation of scientific minds AstraZeneca Post-Doc Programme gives post-doctoral scientists the chance to undertake high-quality, innovative research in a cross-discipline scientific environment within the pharmaceutical industry. AstraZeneca post-doctoral scientists: • Conduct independent, cutting-edge research in state-of-the-art facilities • Collaborate with AstraZeneca scientists in discovery and drug development teams • Work alongside a world-leading academic advisor • Publish their work in high-quality scientific journals and communicate research findings at international scientific conferences. Each scientist receives a tailored training and development programme, aligned with the established AstraZeneca approach to personal development. This includes core training on drug discovery and development, as well as on key skills, such as presentation delivery and publication writing.
  22. 22. AstraZeneca Internal Post-doc Program Post-doc proposal selection based on • Scientific Novelty • Feasability (Scientific, Technical and 2 yr time frame) • Availability of academic collaborator For more information on the opportunities of the programme, visit: expandspostdoc-program For the latest vacancies, visit: program2/
  23. 23. Graduate vacancies for AZ Sweden are now live with a closing date of the 19th May 2013. AstraZeneca R&D Mölndal To push the boundaries of science to deliver life-changing medicines
  24. 24. and discussion questions ?? 25
  25. 25. Topushtheboundariesofsciencetodeliverlife-changingmedicines >20 Clinical ready compounds >40 Mechanistic tool compounds up to $100K grants Potential to partner your molecules Prizes for solutions to R&D challenges Partnerships New clinically validated projects New lead optimization projects New targets/hit ID projects Access to novel molecules Novel solutions Clinical Compound Bank Pharmacology Toolbox Target Innovation New Molecule Profiling R&D Challenges Suggestion Box Ideas for future partnerships Academics Why is it Attractive? AZ GenerationofNoveldataforpublicationsandadvancemedicalscience
  26. 26. A global business 50,000 employees. Research across 3 continents. $4.2 billion invested in R&D in 2013. Manufacturing in 17 countries. Sales in 100 countries. $25.7 billion sales in 2013.
  27. 27. AstraZeneca Mölndal 2 150 900 1 100 >250 employees in Innovative Medicines in Global Medicines Development colleagues from 30 countries 1 614 with academic degree 574 PhDs 3